C. C. Tsai

Enable Biosciences (United States)

Papers

1

Total Citations

32

H-Index

1

About

Dr. C. C. Tsai has made pivotal contributions to biomedical engineering and infectious disease diagnostics, with a primary focus on developing high-throughput, automated platforms for serological testing. Their most cited work, published in 2020, introduced a sensitive and specific method for detecting SARS-CoV-2 antibodies using a fully automated liquid-handling robotic system—a critical innovation during the COVID-19 pandemic. This study, which has garnered 32 citations, addressed the urgent need for scalable community screening and infection prevalence assessment, enabling rapid and reliable identification of infected individuals. By integrating robotics with serological assays, Dr. Tsai’s research significantly enhanced testing capacity and accuracy, directly supporting global pandemic response efforts. Beyond this landmark paper, their work exemplifies the intersection of automation and clinical diagnostics, paving the way for more efficient public health surveillance. Dr. Tsai’s contributions underscore a commitment to translating engineering solutions into real-world medical applications, making their research indispensable for students and professionals advancing diagnostic technologies in emerging infectious disease contexts.

Research Focus

Key Achievements

1
H-Index
1
Papers
32
Total Citations
32
Avg Citations/Paper
🏆 Most Cited Paper
Sensitive and Specific Detection of SARS-CoV-2 Antibodies Using a High-Throughput, Fully Automated Liquid-Handling Robotic System
32 citations · 2020
📈 Most Prolific Year: 2020 (1 Papers)
🤝 Key Collaborators: 9
🏛 Institutions: Enable Biosciences (United States)

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 4 days ago